Mississippi could get more than $6 million as part of a nationwide settlement from opioid drug makers. Mississippi Attorney ...

Viatris Inc. (Nasdaq: VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the ...

Segmentation Outlook The smart pill boxes & bottles market can be segmented based on product type, end-user, technology, and distribution channel. Product segmentation typically divides devices into ...

Dear Heloise: When it’s time to restock your pill dispenser from your personal pharmacy, it can be challenging to remember which time of day to take them or how many pills to take. To make this ...

Viatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS guidance.

Viatris (VTRS) stock rises in reaction to positive Phase 3 trial results and its better-than-expected Q1 2025 financials. Read more here.

Drugmaker Viatris beat Wall Street estimates for first-quarter profit and revenue on Thursday, helped by sales of its branded drugs in China.

Three analysts surveyed by Zacks expected $3.23 billion. Viatris expects full-year earnings in the range of $2.16 to $2.30 per share, with revenue in the range of $13.5 billion to $14 billion. _____ ...

In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against other Billionaire Ken Fisher’s healthcare stock picks with massive upside potential.

(Reuters) -Viatris said on Monday it would pay up to $335 million over nine years as part of a nationwide settlement to resolve claims by U.S. state and local governments that it fueled an ...